JP2019519546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519546A5 JP2019519546A5 JP2018565674A JP2018565674A JP2019519546A5 JP 2019519546 A5 JP2019519546 A5 JP 2019519546A5 JP 2018565674 A JP2018565674 A JP 2018565674A JP 2018565674 A JP2018565674 A JP 2018565674A JP 2019519546 A5 JP2019519546 A5 JP 2019519546A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- sequence
- bmp6
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 122
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 118
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 106
- 239000005557 antagonist Substances 0.000 claims description 102
- 102000008857 Ferritin Human genes 0.000 claims description 74
- 108050000784 Ferritin Proteins 0.000 claims description 74
- 238000008416 Ferritin Methods 0.000 claims description 72
- 239000012472 biological sample Substances 0.000 claims description 56
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 239000012634 fragment Substances 0.000 claims description 51
- 208000007502 anemia Diseases 0.000 claims description 50
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- 102000003951 Erythropoietin Human genes 0.000 claims description 12
- 108090000394 Erythropoietin Proteins 0.000 claims description 12
- 102000001554 Hemoglobins Human genes 0.000 claims description 12
- 108010054147 Hemoglobins Proteins 0.000 claims description 12
- 229940105423 erythropoietin Drugs 0.000 claims description 12
- 102000046095 human BMP6 Human genes 0.000 claims description 12
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 12
- 229910052742 iron Inorganic materials 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 8
- 102000046107 human BMP7 Human genes 0.000 claims description 8
- 210000001995 reticulocyte Anatomy 0.000 claims description 8
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 6
- 102000045896 human BMP2 Human genes 0.000 claims description 6
- 102000004338 Transferrin Human genes 0.000 claims description 5
- 108090000901 Transferrin Proteins 0.000 claims description 5
- 239000012581 transferrin Substances 0.000 claims description 5
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 claims description 4
- 208000017667 Chronic Disease Diseases 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 4
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 claims description 4
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000004820 blood count Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 238000005534 hematocrit Methods 0.000 claims description 4
- 102000018511 hepcidin Human genes 0.000 claims description 4
- 108060003558 hepcidin Proteins 0.000 claims description 4
- 229940066919 hepcidin Drugs 0.000 claims description 4
- 102000046096 human BMP5 Human genes 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 230000010437 erythropoiesis Effects 0.000 claims description 2
- 210000003608 fece Anatomy 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000001631 haemodialysis Methods 0.000 claims description 2
- 230000000322 hemodialysis Effects 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 229940127121 immunoconjugate Drugs 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 76
- 230000004044 response Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 102000016359 Fibronectins Human genes 0.000 description 9
- 108010067306 Fibronectins Proteins 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 102000008102 Ankyrins Human genes 0.000 description 4
- 108010049777 Ankyrins Proteins 0.000 description 4
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 4
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 102000013069 gamma-Crystallins Human genes 0.000 description 3
- 108010079934 gamma-Crystallins Proteins 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- -1 Fabs Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000255972 Pieris <butterfly> Species 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350257P | 2016-06-15 | 2016-06-15 | |
| US62/350,257 | 2016-06-15 | ||
| PCT/IB2017/053507 WO2017216724A1 (en) | 2016-06-15 | 2017-06-13 | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519546A JP2019519546A (ja) | 2019-07-11 |
| JP2019519546A5 true JP2019519546A5 (OSRAM) | 2020-07-27 |
| JP7231411B2 JP7231411B2 (ja) | 2023-03-01 |
Family
ID=59239934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565674A Active JP7231411B2 (ja) | 2016-06-15 | 2017-06-13 | 骨形成タンパク質６（ｂｍｐ６）の阻害剤を使用して疾患を処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11434269B2 (OSRAM) |
| EP (1) | EP3471759A1 (OSRAM) |
| JP (1) | JP7231411B2 (OSRAM) |
| KR (1) | KR102492057B1 (OSRAM) |
| CN (1) | CN110381988A (OSRAM) |
| AU (1) | AU2017283787B2 (OSRAM) |
| CA (1) | CA3027651A1 (OSRAM) |
| IL (1) | IL263664A (OSRAM) |
| WO (1) | WO2017216724A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2550114A (en) | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
| US12089930B2 (en) | 2018-03-05 | 2024-09-17 | Marquette University | Method and apparatus for non-invasive hemoglobin level prediction |
| US20210196823A1 (en) * | 2018-06-08 | 2021-07-01 | Pfizer Inc. | Methods of Treating Metabolic Disease |
| GB201815629D0 (en) * | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
| WO2020257587A1 (en) * | 2019-06-19 | 2020-12-24 | Cornell University | Methods of promoting erythropoiesis and overcoming erythropoitein resistance in patients |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| CN114075287B (zh) * | 2020-08-18 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化bcma抗体和bcma-car-t细胞 |
| KR20240062222A (ko) | 2022-10-28 | 2024-05-09 | 안재남 | IoT 동작 기기 제어용 디지털 통신 시스템 및 그 구동방법 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| JPH02500329A (ja) | 1987-05-21 | 1990-02-08 | クリエイテイブ・バイオマリキユールズ・インコーポレーテツド | ターゲット化多機能蛋白質 |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5242813A (en) | 1990-10-12 | 1993-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors |
| DE69123241T2 (de) | 1990-12-14 | 1997-04-17 | Cell Genesys Inc | Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen |
| ES2145004T3 (es) | 1991-08-21 | 2000-07-01 | Novartis Ag | Derivados de anticuerpos. |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5610021A (en) | 1992-02-21 | 1997-03-11 | Creative Biomolecules, Inc. | Compositions and methods for identification and use of soluble complex forms of osteogenic proteins |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| JPH09512910A (ja) | 1994-05-04 | 1997-12-22 | マウント・サイナイ・ホスピタル・コーポレイション | ＴＧＦ−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法 |
| MX9700764A (es) | 1994-07-29 | 1997-05-31 | Smithkline Beecham Plc | Compuestos novedosos. |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1996039518A1 (en) | 1995-06-05 | 1996-12-12 | Bionebraska, Inc. | Lead binding polypeptides and nucleotides coding therefor |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| ES2231991T3 (es) | 1997-06-11 | 2005-05-16 | Borean Pharma A/S | Modulo de trimerizacion. |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| AU3672800A (en) | 1999-04-09 | 2000-11-14 | Kyowa Hakko Kogyo Co. Ltd. | Method for controlling the activity of immunologically functional molecule |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2441903C (en) | 2000-05-26 | 2012-07-31 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| ES2405944T3 (es) | 2000-11-30 | 2013-06-04 | Medarex, Inc. | Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas |
| EP1456360B1 (en) | 2001-04-19 | 2015-06-03 | The Scripps Research Institute | Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| JP2004532038A (ja) | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US20030157579A1 (en) | 2002-02-14 | 2003-08-21 | Kalobios, Inc. | Molecular sensors activated by disinhibition |
| US7335478B2 (en) | 2002-04-18 | 2008-02-26 | Kalobios Pharmaceuticals, Inc. | Reactivation-based molecular interaction sensors |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| US20050008625A1 (en) | 2003-02-13 | 2005-01-13 | Kalobios, Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| ES2547866T3 (es) | 2005-02-16 | 2015-10-09 | The General Hospital Corporation | Uso de proteínas de fusión de hemojuvelina para regular el metabolismo del hierro mediado por hepcidina |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| RU2461572C2 (ru) | 2006-06-07 | 2012-09-20 | Биоэллаенс К.В. | Антитела, распознающие содержащий углеводы эпитоп на cd-43 и сеа, экспрессируемых на злокачественных клетках, и способы их применения |
| JP2010503383A (ja) | 2006-09-12 | 2010-02-04 | ザ ジェネラル ホスピタル コーポレイション | 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法 |
| JP2010539932A (ja) | 2007-09-28 | 2010-12-24 | ストライカー コーポレイション | 骨形成タンパク質に対する中和抗体を検出するための方法 |
| CA3019967A1 (en) | 2008-11-13 | 2010-05-20 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation of bmp-6 |
| US20140086919A1 (en) | 2012-09-24 | 2014-03-27 | Herbert Y. Lin | Methods and compositons for regulating iron homeostasis by modulation of bmp-6 |
| US20110070242A1 (en) | 2009-09-01 | 2011-03-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for Diagnosing and Treating Iron Dysregulation |
| RU2620071C2 (ru) * | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| AU2012251919B2 (en) | 2011-01-19 | 2016-12-15 | Ferrumax Pharmaceuticals, Inc. | Compositions for regulating iron homeostasis and methods of using same |
| WO2012151609A1 (en) | 2011-05-06 | 2012-11-15 | Women's And Children's Health Research Institute Inc | Method of treatment and prophylaxis of pathologies of the bone |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MX356933B (es) * | 2011-12-14 | 2018-06-20 | Abbvie Deutschland | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. |
| CA2874117C (en) * | 2012-07-02 | 2021-10-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia |
| AR093620A1 (es) * | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| US9139648B1 (en) * | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
-
2017
- 2017-06-13 US US16/464,113 patent/US11434269B2/en active Active
- 2017-06-13 WO PCT/IB2017/053507 patent/WO2017216724A1/en not_active Ceased
- 2017-06-13 KR KR1020197001175A patent/KR102492057B1/ko active Active
- 2017-06-13 EP EP17733900.9A patent/EP3471759A1/en not_active Withdrawn
- 2017-06-13 CN CN201780049356.6A patent/CN110381988A/zh active Pending
- 2017-06-13 CA CA3027651A patent/CA3027651A1/en active Pending
- 2017-06-13 JP JP2018565674A patent/JP7231411B2/ja active Active
- 2017-06-13 AU AU2017283787A patent/AU2017283787B2/en not_active Ceased
-
2018
- 2018-12-12 IL IL263664A patent/IL263664A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519546A5 (OSRAM) | ||
| JP6675739B2 (ja) | 新規抗ｐａｄ４抗体 | |
| CN102065888B (zh) | 抗-vegf抗体 | |
| CN107531783B (zh) | 靶向bmp6抗体的组合物和方法 | |
| EP3753951A1 (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| TW201833141A (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| AU2016301969B2 (en) | Novel anti-human GPVI antibodies and uses thereof | |
| JP6105146B2 (ja) | Ｐａｎ−ＥＬＲ＋ＣＸＣケモカイン抗体 | |
| JP2023537958A (ja) | Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子 | |
| WO2019131769A1 (ja) | 新規抗ｐａｄ４抗体 | |
| US12440561B2 (en) | Method of diagnosis and treatment of rheumatoid arthritis | |
| CN105934444A (zh) | 针对免疫细胞受体和tlr信号传导自身抗原的双重特异性结合蛋白 | |
| AU2018214222B2 (en) | Inhibition of platelet aggregation using anti-human GPVI antibodies | |
| TWI882142B (zh) | 抗FXI/FXIa抗體、其抗原結合片段及醫藥用途 | |
| CN112136049A (zh) | 用于定量和修饰蛋白质粘度的系统和方法 | |
| US10647766B2 (en) | Anti-CXCL12 antibody molecules and their uses | |
| AU2024253832A1 (en) | Anti-tmprss6 antibodies and uses thereof | |
| JP2024512299A (ja) | タンパク質の粘度を定量及び変更するためのシステム及び方法 | |
| RU2019100545A (ru) | Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6) |